42465-54-3

Usage

Uses

Used in Pharmaceutical Synthesis:
Ethanone,1-(2-amino-3-methoxyphenyl)is used as a key intermediate in the production of various pharmaceutical drugs. Its unique chemical structure allows it to be a versatile building block in the synthesis of a wide range of medicinal compounds.
Used in Research and Development:
In the field of research and development, Ethanone,1-(2-amino-3-methoxyphenyl)is utilized for the exploration of new chemical reactions and the development of novel organic compounds. Its properties make it a valuable tool for scientists working in medicinal chemistry and drug discovery.
Used in Medicinal Chemistry:
Ethanone,1-(2-amino-3-methoxyphenyl)is used as a starting material in the design and synthesis of new pharmaceutical agents. Its unique structure and reactivity contribute to the development of innovative drugs with potential therapeutic applications.
Used in Drug Discovery:
Due to its potential applications in medicinal chemistry, Ethanone,1-(2-amino-3-methoxyphenyl)is also used in drug discovery processes. It aids in the identification and optimization of new drug candidates, contributing to the advancement of pharmaceutical research.

InChI:InChI=1/C9H11NO2/c1-6(11)7-4-3-5-8(12-2)9(7)10/h3-5H,10H2,1-2H3

Upstream product

• 586-37-8 1-(3-Methoxyphenyl)ethanone 
• 4502-10-7 2'-amino-3'-hydroxyacetophenone 
• 74-88-4 methyl iodide 
• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 917-54-4 methyllithium 
• 941-55-9 4-toluenesulfonyl azide 
• 33852-43-6 1-(3-methoxy-2-nitrophenyl)ethanone 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 15865-57-3 2-nitro-3-methoxybenzoyl chloride 

Downstream Products

• 873995-53-0 2-(2-amino-3-methoxyphenyl)propan-2-ol 
• 950818-63-0 CH₂OC₁₄H₁₉ON 
• 950818-71-0 2-(2-amino-3-methoxyphenyl)-5,5-dimethylhex-3-yn-2-ol 
• 950818-67-4 C₁₄H₁₅ONC₂CH₂O 
• 194782-60-0 2-isopropenyl-6-methoxy-aniline 
• 90417-27-9 8-methoxy-1H-cinnolin-4-one 
• 1204652-09-4 3-[2-chloro-3-(trifluoromethyl)phenyl]-1-(2,4-difluorobenzyl)-8-methoxycinnolin-4(1H)-one 
• 33844-20-1 3-bromo-8-methoxy-1H-cinnolin-4-one 
• 1204652-86-7 3-Bromo-1-(2,4-difluorobenzyl)-8-methoxycinnolin-4(1H)-one 
• 90417-27-9 8-methoxy-1H-cinnolin-4-one 
• 1429782-06-8 C₁₁H₁₀Cl₃NO₃ 
• 953039-90-2 2-chloro-8-methoxy-4-methyl-quinazoline 
• 1027948-75-9 N-(2-{3-[2-(tert-butyl-dimethyl-silanyloxy)-phenyl]-3-oxo-propionyl}-6-methoxy-phenyl)-2,2-dimethyl-propionamide 

Relevant academic research and scientific papers

A Convenient Formal [4+2] Heterocylization Route to Bis(triflyl)tetrahydroquinolines

We report the sustainable and efficient synthesis of a new type of quinoline derivatives bearing one or two SO2CF3 groups. The protocol is metal-, catalyst- and irradiation-free, involves the use of readily available and stable precursors, and avoids the formation of side products. Also, the mild conditions of the process allow the tolerance of a wide range of functional groups.

Novel 4-(1H-1,2,3-triazol-4-yl)methoxy)cinnolines as potent antibacterial agents: Synthesis and molecular docking study

A new series of cinnoline-1,2,3-triazole derivatives were designed and synthesized by adopting Cu(1) catalyzed regeoselective1,3-dipolar cycloaddition reaction of terminal alkyne and azide. The in vitro antibacterial activity of all these compounds revealed that compounds 9d, 10a, 10b, and 10c are more potent antibacterial agents. Among the series, compound 4-(3-(4-((cinnolin-4-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)morpholine (10b) exhibited the most potent antibacterial activity against all tested gram-positive and gram-negative bacterial strains. Furthermore, molecular docking studies were also performed to understand the binding interactions of the most active analogs 9d, 10a, 10b, and 10c with Elastase of Pseudomonas aeruginosa (PDB: 1U4G). The results indicated that these classes of compounds have potential antibacterial activity, especially the compound 10b may serve as a promising antibacterial lead compound that could be further optimized for the further development of antibacterial drugs.

Design, synthesis, and biological evaluation of 4-Methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases

Polypharmacology is a promising paradigm in modern drug discovery. Herein, we have discovered a series of novel PI3K and HDAC dual inhibitors in which the hydroxamic acid moiety as the zinc binding functional group was introduced to a quinazoline-based PI3K pharmacophore through an appropriate linker. Systematic structure-activity relationship studies resulted in lead compounds 23 and 36 that simultaneously inhibited PI3K and HDAC with nanomolar potencies and demonstrated favorable antiproliferative activities. Compounds 23 and 36 efficiently modulated the expression of p-AKT and Ac-H3, arrested the cell cycle, and induced apoptosis in HCT116 cancer cells. Following pharmacokinetic studies, 23 was further evaluated in HCT116 and HGC-27 xenograft models to show significant in vivo anticancer efficacies with tumor growth inhibitions of 45.8% (po, 150 mg/kg) and 62.6% (ip, 30 mg/kg), respectively. Overall, this work shows promise in discovering new anticancer therapeutics by the approach of simultaneously targeting PI3K and HDAC pathways with a single molecule.

QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS

This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The pr

Ru(ii)-catalyzed intermolecular ortho-C-H amidation of aromatic ketones with sulfonyl azides

Ru(ii)-catalyzed intermolecular ortho-C-H amidation of weakly coordinating aromatic ketones with sulfonyl azides is reported. The developed reaction protocol can be extended to various substituted aromatic ketones to afford a wide range of desired C-N bond formation products in good yields.

SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME

The subject of the present invention is compounds corresponding to the formula (I) in which: X represents a divalent (C2-C5)alkylene radical which is unsubstituted or substituted one or more times by an Alk group; R1 represents a phenyl, a naphthyl, a pyridyl, a 1-benzothienyl or a 1,3-benzodioxolyl; R2 represents a hydrogen atom, a halogen atom, an Alk group, an OAlk group or else a group chosen from —S-Alk, —SO-Alk, —SO2-Alk, —CO—N(R4)-Alk, —N(R4)SO2-Alk, —N(R4)CO-Alk, —N(R4)SO2—N(Alk)2; R3 represents a hydrogen atom, a halogen atom, an Alk group or an OAlk group; R4 represents a hydrogen atom or a (C1-C4)alkyl; Alk represents an unsubstituted or substituted (C1-C4)alkyl. Preparation process and therapeutic application.

SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF

The present invention is related to novel substituted 1-benzylcinnolin-4(1H)-one derivatives having affinity for cannabinoid CB2 receptors, their preparation and their therapeutic application.

Novel and convenient synthesis of substituted quinolines by copper- or palladium-catalyzed cyclodehydration of 1-(2-aminoaryl)-2-yn-1-ols

(Chemical Equation Presented) A general and convenient synthesis of substituted quinolines by regioselective copper- or palladium-catalyzed 6-endo-dig cyclization-dehydration of 1-(2-aminoaryl)-2-yn-1-ols is reported. The crude substrates were easily obtained by the Grignard reaction between the appropriate alkynylmagnesium bromide and 2-aminoaryl ketones and could be used without further purification for the subsequent cyclization step. Heteroannulation reactions were carried out in MeOH or DME as the solvent at 60 or 100°C in the presence of CuCl2 or PdX2 (in conjunction with 10 equiv of KX, X = Cl, I) as the catalyst to afford the quinoline derivatives in good to excellent isolated yields based on starting 1-(2-aminoaryl)-2-yn-1-ols (66-90%).

QUINAZOLINES FOR PDK1 INHIBITION

The invention provides novel quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.

8-Alkoxy or cycloalkoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamines

The present invention relates to compounds of formula wherein R1, R2, R3, and n are as described in the specification and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I can be used for the treatment of 5-HT5A receptor antagonists related diseases, which include depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, disorders of eating behaviors, sexual dysfunction, sleep disorders, withdrawal from abuse of drugs, motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders and gastrointestinal disorders such as irritable bowel syndrome.